A detailed history of Driehaus Capital Management LLC transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Driehaus Capital Management LLC holds 1,617,628 shares of ATXS stock, worth $15.2 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares
1,617,628
Previous 1,749,922 7.56%
Holding current value
$15.2 Million
Previous $15.9 Million 11.84%
% of portfolio
0.17%
Previous 0.17%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$8.97 - $12.65 $1.19 Million - $1.67 Million
-132,294 Reduced 7.56%
1,617,628 $17.8 Million
Q2 2024

Aug 14, 2024

SELL
$8.83 - $13.51 $132,953 - $203,420
-15,057 Reduced 0.85%
1,749,922 $15.9 Million
Q1 2024

May 15, 2024

BUY
$6.99 - $16.69 $9.36 Million - $22.4 Million
1,339,615 Added 314.93%
1,764,979 $24.8 Million
Q4 2023

Feb 14, 2024

SELL
$4.42 - $8.06 $4.55 Million - $8.29 Million
-1,028,840 Reduced 70.75%
425,364 $3.27 Million
Q3 2023

Nov 14, 2023

SELL
$6.89 - $9.86 $9,949 - $14,237
-1,444 Reduced 0.1%
1,454,204 $10.8 Million
Q2 2023

Aug 14, 2023

BUY
$8.33 - $13.72 $191,373 - $315,203
22,974 Added 1.6%
1,455,648 $12.1 Million
Q1 2023

May 15, 2023

BUY
$11.2 - $15.79 $1.07 Million - $1.51 Million
95,359 Added 7.13%
1,432,674 $19.1 Million
Q4 2022

Feb 14, 2023

BUY
$7.44 - $14.89 $5.07 Million - $10.1 Million
680,954 Added 103.75%
1,337,315 $19.9 Million
Q3 2022

Nov 14, 2022

BUY
$2.97 - $10.34 $1.95 Million - $6.79 Million
656,361 New
656,361 $5.93 Million

Others Institutions Holding ATXS

About Astria Therapeutics, Inc.


  • Ticker ATXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,178,000
  • Market Cap $143M
  • Description
  • Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...
More about ATXS
Track This Portfolio

Track Driehaus Capital Management LLC Portfolio

Follow Driehaus Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Driehaus Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Driehaus Capital Management LLC with notifications on news.